Vienna group makes vaccine headway in toxic shock syndrome

vienna

Decades after the condition was first documented in the 1980s, researchers say they have made the world’s first vaccine for toxic shock syndrome. In an early study, the vaccine--developed from detoxified Staphylococcus--was found to be safe and effective.

A joint effort between staff at the Medical University of Vienna’s Department of Clinical Pharmacology and the Vienna biopharma Biomedizinische Forschungsgesellschaft mbH tested the experimental vaccine in 46 young men and women. Phase I results demonstrated that the vaccine has “practically no side effects,” according to the team’s statement. When injected into skin, the vaccine induces the production of antibodies that kick into gear upon detecting a risk, the team said.

Bernd Jilma, an associate professor at MedUni Vienna, said the vaccine's interaction with the body is similar to a tetanus vaccination, explaining the immunization “lasts for 5 years or more.”

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

A life-threatening complication of infection by S. aureus or group A streptococcus bacteria, TSS has typically been connected with use of superabsorbent tampons, according to Mayo Clinic. Symptoms include high fever, vomiting, low blood pressure or a rash. Though very rare, it can lead to organ failure and impact anyone.

"Nevertheless, in 50% of cases the disease is associated with menstruation in young women," Jilma said in the statement. Those with a compromised immune system stand at a greater risk, and so could be “preventively vaccinated,” the team concluded.

Next up is a Phase II trial, which the group says is underway and seeking volunteers. The vaccine is “some years” away from clinical use, Biomedizinische Forschungsgesellscaft mbH director Martha Eibl said in the release.

The Phase I results were published in The Lancet Infectious Diseases.

- here’s the release
- and the abstract

Related Articles:
Expect vaccines market to swell to $40B by 2020: Tufts CSDD
Astellas, ClearPath launch vaccines firm aimed at healthcare-associated infections

Read more on

Suggested Articles

Roche's Perjeta is looking to build its case as an add-on treatment to standard-of-care Herceptin plus chemo in HER2-positive breast cancer patients.

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.